Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-7 loaded exosomes are an experimental therapeutic modality utilizing extracellular vesicles (exosomes) to deliver microRNA-7 (miR-7) to target cells, primarily for the treatment of various cancers such as glioblastoma and pancreatic adenocarcinoma. miR-7 is a potent tumor suppressor that downregulates multiple oncogenic signaling pathways by binding to the 3' untranslated regions (UTRs) of target mRNAs, including EGFR, IGF-1R, and members of the PI3K/Akt pathway. By encapsulating miR-7 within exosomes—often derived from mesenchymal stem cells (MSCs) or engineered donor cells—the microRNA is protected from degradation in the systemic circulation and can be delivered with enhanced bioavailability and potentially reduced immunogenicity compared to synthetic nanoparticles. This approach aims to restore miR-7 levels in tumors where it is frequently downregulated, thereby inhibiting cell proliferation, migration, and angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-7 loaded exosomes.